Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How

Premiere Date: Tuesday, August 31, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, August 31, 2022
Note: Credit Is No Longer Available


Gregory Huhn, MD, MPHTMGregory Huhn, MD, MPHTM 
COVID-19 Vaccination Coordinator and Senior Director of HIV Services, Cook County Health
Associate Professor, Department of Internal Medicine, Division of Infectious Disease
Rush University Medical Center
Chicago, IL

Statement of Need

When selecting efficient treatment regimens for specific HIV-positive patient populations, including patients that have experienced treatment failure, pediatric patients, and Black/African American patients, it is imperative that clinicians utilize strategic protocols to safely switch treatment regimens. This includes reviewing patients’ full treatment history, reviewing active medication lists, and considering patient preference, as well as monitoring patients after switching. This CME Outfitters BriefCase introduces Jeff, a 31-year-old African American infected with HIV perinatally, and discusses the when and how of switching antiretroviral therapy (ART) based on safety and efficacy data.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Integrate best practices for initiating and switching patients to ART based on safety and efficacy profiles.
  • Translate emerging data from national conferences to treatment decisions in clinical practice.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Physicians, PAs, nurse practitioners, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Huhn reports that he receives grants and research support from Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare. He is on the advisory board for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download